Anixa Biosciences (NASDAQ:ANIX) Director Acquires $23,840.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Lewis Titterton, Jr. acquired 8,000 shares of the business’s stock in a transaction that occurred on Friday, October 23rd. The shares were purchased at an average price of $2.98 per share, with a total value of $23,840.00. Following the completion of the acquisition, the director owned 1,054,003 shares of the company’s stock, valued at $3,140,928.94. This represents a 0.76% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Anixa Biosciences Trading Up 2.7%

ANIX opened at $3.37 on Thursday. The stock has a fifty day moving average price of $2.99 and a 200 day moving average price of $2.97. Anixa Biosciences Inc has a 1 year low of $2.32 and a 1 year high of $5.46. The stock has a market cap of $117.14 million, a price-to-earnings ratio of -10.53 and a beta of 0.47.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). As a group, sell-side analysts forecast that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Anixa Biosciences in the 2nd quarter valued at approximately $559,000. GSA Capital Partners LLP bought a new position in Anixa Biosciences in the 2nd quarter worth approximately $329,000. CoreCap Advisors LLC lifted its holdings in shares of Anixa Biosciences by 19.2% during the third quarter. CoreCap Advisors LLC now owns 62,020 shares of the company’s stock worth $182,000 after buying an additional 10,000 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Anixa Biosciences by 13.6% during the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after buying an additional 7,300 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Anixa Biosciences in the second quarter valued at approximately $133,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ANIX has been the topic of several recent research reports. Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Weiss Ratings upgraded shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Tuesday, October 6th. Finally, HC Wainwright dropped their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, September 22nd. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company’s programs are designed to use the immune system to identify and attack disease-associated targets.

Anixa’s oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.